Abstract:A current in silico study investigates baxdrostat and 22 related compounds for their affinity to aldosterone synthase through molecular docking. Molecular dynamics simulation assesses the stability of these compound‐protein complexes. Drug‐likeness and ADMET properties are under scrutiny, complemented by a review of existing in vitro and in vivo studies. Resistant hypertension, a severe condition affecting about 10 % of people with high blood pressure, significantly increases the risk of heart, brain, and kidney issues. This study investigates the potential of baxdrostat and its derivatives (1–22) as aldosterone synthase inhibitors for resistant hypertension using in silico methods. The study employed various computational methods, including molecular dynamics simulation (MD), molecular docking, frontier molecular orbital (FMO) analysis, and global chemical descriptors, to evaluate the interactions between the compounds and the target proteins. The docking results showed that compounds 2, 5, 7, and baxdrostat had binding affinities of −7.8 kcal/mol, −10.9 kcal/mol, −10.6 kcal/mol, and −9.3 kcal/mol, respectively. Additionally, molecular dynamics simulations revealed that ligands 2, 5, and baxdrostat formed the most stable protein‐ligand complexes with aldosterone synthase. The complex of the 4FDH‐baxdrostat remained highly stable across all tested temperatures (300 K, 305 K, 310 K, and 320 K), consistently displaying low RMSD values, with the minimum observed at 305 K. Baxdrostat emerges as the most promising candidate among the compounds examined, showcasing notable potential when considering a combination of in vitro, in vivo, and now in silico data. While baxdrostat remains the primary candidate based on comprehensive in vitro, in vivo, and in silico studies, further analysis using FMO theory suggests that ligands 2 and 5 have promising potential due to their smaller Egap. To validate these findings, further clinical investigations are warranted.

Design, synthesis and biological evaluation of pyridyl substituted benzoxazepinones as potent and selective inhibitors of aldosterone synthase

Discovery of Benzimidazole Derivatives as Novel Aldosterone Synthase Inhibitors: QSAR, Docking Studies, and Molecular Dynamics Simulation?

Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase

Synthesis, Crystal Structures, Fluorescence and Xanthine Oxidase Inhibitory Activity of Pyrazole-Based 1,3,4-Oxadiazole Derivatives

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

Emerging trends in small molecule inhibitors targeting aldosterone synthase: A new paradigm in cardiovascular disease treatment

Discovery of Novel Pyrazole-Based Selective Aldosterone Synthase (CYP11B2) Inhibitors: A New Template to Coordinate the Heme-Iron Motif of CYP11B2

Design of Novel Thiazole Bearing Pyrazole Derivatives and Their Dual Activities as ACE Inhibitors and Calcium Channel Blockers in Cardiovascular Disease

A Patent Review of Aldosterone Synthase Inhibitors (2014-Present)

The development of a whole-cell based medium throughput screening system for the discovery of human aldosterone synthase (CYP11B2) inhibitors: Old drugs disclose new applications for the therapy of congestive heart failure, myocardial fibrosis and hypertension

Dihydrobenzoxazinone derivatives as aldose reductase inhibitors with antioxidant activity

Design, synthesis and biological evaluation of novel pyxinol derivatives with anti-heart failure activity

Design, Synthesis and Biological Evaluation of 6-Substituted Aminocarbonyl Benzimidazole Derivatives As Nonpeptidic Angiotensin II AT1 Receptor Antagonists.

Discovery of 4-(isopentyloxy)-3-nitrobenzamide derivatives as xanthine oxidase inhibitors through a non-anthraquinone exploration

Design, Synthesis, and Biological Evaluation of 1,2,4-Triazole Bearing 5-Substituted Biphenyl-2-sulfonamide Derivatives As Potential Antihypertensive Candidates

Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension.

Synthesis and Biological Evaluation of 3-Substituted-4-(quinoxalin-6-yl) Pyrazoles as Selective ALK5 Inhibitors

Design and synthesis of potent and multifunctional aldose reductase inhibitors based on quinoxalinones.

Aldosterone and aldosterone synthase inhibitors in cardiorenal disease

Investigating Baxdrostat and Its Derivatives as Aldosterone Synthase Inhibitors for Resistant Hypertension: An In Silico Approach

Design, synthesis and biological evaluation of N-(4-alkoxy-3-(1H-tetrazol-1-yl)phenyl) heterocyclic aromatic amide derivatives as xanthine oxidase inhibitors